Better Health for All

CASI Pharmaceuticals, Inc. develops and commercializes therapeutics for serious conditions such as cancer, multiple myeloma, leukemia, ovarian cancer, antibody-mediated rejection, and autoimmune diseases.

Its lead drug candidates and commercial products, including ENMD-2076, CID-103, EVOMELA®, FOLOTYN®, and Zimberelimab, are all aimed at treating these conditions, indicating that 100% of its product portfolio delivers revolutionary health benefits. There is no evidence of revenue from products with negative health outcomes. The company conducts clinical trials, with ENMD-2076 having completed Phase I studies and completing data for a Phase II study. However, there is no information regarding the ethical conduct of these trials, diversity of participants, or transparency of results.

Fair Money & Economic Opportunity

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics.

The provided articles confirm its business as pharmaceuticals and biotech. The company does not offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions and their customer-facing financial products, are not applicable to CASI Pharmaceuticals, Inc.

Fair Pay & Worker Respect

As of December 31, 2022, CASI Pharmaceuticals reported that all 86 of its employees were full-time, indicating 0% of the workforce is on insecure contracts.

The company provides a comprehensive benefits program designed to keep employees and their families healthy, which includes medical, dental, vision, legal services, supplemental life insurance, pet insurance, paid parental leave, dependent care, mental health services, and company-sponsored fitness programs. The company's employees are not part of any collective bargaining agreements.

Honest & Fair Business

No specific, concrete evidence was found in the provided articles to assess CASI Pharmaceuticals, Inc. against any of the 'Honest & Fair Business' KPIs. The articles either explicitly state that relevant metrics are not mentioned or provide general information without the quantitative data or specific policy details required by the rubric. For instance, while one article mentions an agreement for independent audits of royalty payments and compliance with anti-corruption laws,

this pertains to a specific contract and does not provide company-wide data on audit coverage or the strength and enforcement of CASI's overall anti-corruption policy.

No War, No Weapons

The provided articles describe CASI Pharmaceuticals, Inc. as a biopharmaceutical company focused on developing therapeutics for hematology-oncology and autoimmune diseases.

The information covers investor relations, corporate governance, including a Code of Ethics, and details about investigational products like CID-103. However, none of the articles contain specific, concrete data points or explicit statements regarding revenue from arms contracts, dual-use technologies with military applications, sales to embargoed regimes, peacebuilding investments, or any other activities directly relevant to the 'No War, No Weapons' value. Therefore, no KPIs can be scored based on the evidence provided.

Planet-Friendly Business

No specific, concrete data points or facts related to environmental performance, targets, or initiatives for CASI Pharmaceuticals, Inc. were found across any of the provided articles.

The articles primarily focus on financial results, product development, or general industry sustainability trends without company-specific details for CASI. Therefore, no KPIs under the 'Planet-Friendly Business' value can be scored based on the evidence provided.

Respect for Cultures & Communities

The provided articles do not contain specific, concrete data points for any of the KPIs related to 'Respect for Cultures & Communities'. While CASI Pharmaceuticals has a Code of Ethics

and a Community Grants program , the information available does not detail formal partnerships with indigenous or local community groups , the percentage of revenue reinvested locally , cultural appropriation incidents , cultural impact assessment protocols , local employment ratios , community-specific grievance mechanisms , FPIC participation rates , community governance inclusion , cultural preservation investments , local procurement shares , indigenous supplier counts , cultural site protection , social license to operate , charitable giving specifically to cultural heritage organizations , community fund allocations from non-core revenue , language inclusivity scores , cultural incident response frameworks , or cultural sensitivity training completion rates . The community grants mentioned are for general community support, such as career development and empowerment , not specifically cultural heritage or preservation .

Safe & Smart Tech

CASI Pharmaceuticals provides users with rights to access, update, object to, restrict, and request deletion of their personal data, and to withdraw consent.

Users can also unsubscribe from emails and reject analytic and advertising cookies. However, the company reserves the right to retain or delete user information or content, and users agree to CASI using their information in accordance with the Privacy Policy. For data minimization, CASI states it retains personal information for no longer than necessary for stated purposes and endeavors to isolate personal data from non-PII. The company uses essential, analytic, and advertising cookies, with retention periods for analytic and advertising cookies varying from 24 hours to 24 months. For regulatory compliance, CASI's terms of service are governed by the laws of the People's Republic of China, with disputes handled in Shenzhen, Guangdong Province. The company states it processes personal data following applicable laws and may disclose data to law enforcement to comply with legal requirements, including using legal mechanisms like standard contractual clauses for EU data transfers.